These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12548114)

  • 41. Critical Analysis of Markov Models Used for the Economic Evaluation of Colorectal Cancer Screening: A Systematic Review.
    Silva-Illanes N; Espinoza M
    Value Health; 2018 Jul; 21(7):858-873. PubMed ID: 30005759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods.
    Yamamoto M; Nakama H
    Hepatogastroenterology; 2000; 47(32):396-9. PubMed ID: 10791199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population screening for colorectal carcinoma with fecal-occult blood testing: are we sufficiently informed?
    Agrez MV; Coory M; Cockburn J
    Cancer; 1998 May; 82(10):1803-7. PubMed ID: 9587111
    [No Abstract]   [Full Text] [Related]  

  • 45. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model.
    Arrospide A; Idigoras I; Mar J; de Koning H; van der Meulen M; Soto-Gordoa M; Martinez-Llorente JM; Portillo I; Arana-Arri E; Ibarrondo O; Lansdorp-Vogelaar I
    BMC Cancer; 2018 Apr; 18(1):464. PubMed ID: 29695234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost effectiveness of colorectal cancer screening in the elderly.
    Wagner JL; Herdman RC; Wadhwa S
    Ann Intern Med; 1991 Nov; 115(10):807-17. PubMed ID: 1929029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force.
    Pignone M; Saha S; Hoerger T; Mandelblatt J
    Ann Intern Med; 2002 Jul; 137(2):96-104. PubMed ID: 12118964
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Screening for colorectal cancer.
    Budenholzer B
    CMAJ; 2001 Apr; 164(7):965-6; author reply 967-8. PubMed ID: 11314442
    [No Abstract]   [Full Text] [Related]  

  • 50. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test.
    Heresbach D; Manfredi S; D'halluin PN; Bretagne JF; Branger B
    Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):427-33. PubMed ID: 16538116
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial.
    De Mil R; Guillaume E; Guittet L; Dejardin O; Bouvier V; Pornet C; Christophe V; Notari A; Delattre-Massy H; De Seze C; Peng J; Launoy G; Berchi C
    Value Health; 2018 Jun; 21(6):685-691. PubMed ID: 29909873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endoscopist-directed propofol administration versus anesthesiologist assistance for colorectal cancer screening: a cost-effectiveness analysis.
    Hassan C; Rex DK; Cooper GS; Benamouzig R
    Endoscopy; 2012 May; 44(5):456-64. PubMed ID: 22531982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost effectiveness of HemoQuant versus Hemoccult for colorectal cancer screening.
    Joseph AM; Crowson TW; Rich EC
    J Gen Intern Med; 1988; 3(2):132-8. PubMed ID: 3128650
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of colorectal cancer screening.
    McMahon PM; Bosch JL; Gleason S; Halpern EF; Lester JS; Gazelle GS
    Radiology; 2001 Apr; 219(1):44-50. PubMed ID: 11274533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Screening for colorectal cancer. French Working Group on Colorectal Cancer Screening.
    Dubois G
    N Engl J Med; 1995 Aug; 333(7):460-1. PubMed ID: 7617006
    [No Abstract]   [Full Text] [Related]  

  • 58. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans.
    Wolf MS; Fitzner KA; Powell EF; McCaffrey KR; Pickard AS; McKoy JM; Lindenberg J; Schumock GT; Carson KR; Ferreira MR; Dolan NC; Bennett CL
    J Clin Oncol; 2005 Dec; 23(34):8877-83. PubMed ID: 16314648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of screening for colorectal cancer in the general population.
    Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
    JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.